Blog
RSS FeedPosted by Michael Wonder on 08 Mar 2022
Key considerations in the health technology assessment of advanced therapy medicinal products in Scotland, The Netherlands and England
8 March 2022 - Advanced therapy medicinal products are highly innovative therapies. Their costs and uncertain value claims have raised concerns ...
Posted by Michael Wonder on 13 Nov 2021
Dutch health insurance: what changes in 2022?
11 November 2021 - The Dutch healthcare institute Zorginstituut Nederland is going to increase its monitoring of treatment to better ...
Posted by Michael Wonder on 02 Sep 2021
Patients in the Netherlands wait 1.5 years for access to new medicines
2 September 2021 - Patients in the Netherlands have to wait an average of 510 days for access to a new ...
Posted by Michael Wonder on 03 Aug 2021
Hansa Biopharma announces reimbursement in the Netherlands of Idefirix (imlifidase) as desensitisation treatment for highly sensitised kidney transplant patients
2 August 2021 - Idefiris (imlifidase) for enabling kidney transplantation in highly sensitised patients is now reimbursable and available for use ...
Posted by Michael Wonder on 10 May 2021
Dutch advisory group says Zolgensma shouldn’t be covered unless Novartis halves price
10 May 2021 - In a challenge to Novartis, a Dutch advisory body has recommended that the government not cover ...
Posted by Michael Wonder on 07 May 2021
World’s most expensive drug may not be covered by Dutch insurance
7 May 2021 - A drug to treat a rare muscle disease which affects some 20 children in the Netherlands ...
Posted by Michael Wonder on 07 Oct 2020
Ineffective treatments to be removed from basic health insurance package
5 October 2020 - Treatments that have not been proven effective will be removed from the Netherlands' basic health insurance package, ...
Posted by Michael Wonder on 07 Jul 2020
Did a pharma trade group try to sabotage a Dutch government report on compulsory licensing?
7 July 2020 - Dutch government commission on compulsory licensing was nearly sabotaged last month after one of its members ...
Posted by Michael Wonder on 08 May 2020
Celltrion’s Remsima SC launches in Netherlands
7 May 2020 - Subcutaneous rheumatoid arthritis treatment Remsima SC launched in the Netherlands, its third European market, Celltrion Healthcare ...
Posted by Michael Wonder on 05 Feb 2020
Five pillars for societal perspective
31 January 2020 - In economic evaluation, the healthcare perspective has gradually given way to use of the societal perspective, as ...
Posted by Michael Wonder on 15 Oct 2019
DIY drugs: should hospitals make their own medicine?
15 October 2019 - If pharmaceutical companies rapidly inflate the price of their products, is there an alternative? One Dutch chemist ...
Posted by Michael Wonder on 02 Sep 2019
Dutch experience demonstrates effective benchmarking of biosimilar use in health systems
31 August 2019 - As medicines become more numerous and often more expensive, health care professionals seek new ways to understand ...
Posted by Michael Wonder on 28 Aug 2019
Dutch health minister threatens to name and shame pharma over prices
28 August 2019 - In an unusual move, the Netherlands health minister wrote an open letter to the pharmaceutical industry ...
Posted by Michael Wonder on 28 Aug 2019
Dutch minister warns big pharma to come clean on drugs prices
27 August 2019 - Health minister Bruno Bruins has warned the pharmaceuticals industry that he considers the way drugs firms ...
Posted by Michael Wonder on 15 Jul 2019
Implementation of “coverage with evidence development” drug approval strategies found lacking
15 July 2019 - Lessons from early deployments in The Netherlands. ...